BACKGROUND: Renal function is often compromised in patients with advanced heart failure. METHODS: We evaluated renal function in heart failure patients supported by the HeartMate II (Thoratec Corporation, Pleasanton, CA) continuous-flow left ventricular assist device (LVAD) who required renal replacement therapy (RRT) by continuous venovenous hemofiltration dialysis (CVVHD) or hemodialysis, or both. Indications for RRT included oliguria (urine < 400 ml/day) unresponsive to diuretic therapy for > 24 hours with a creatinine level > 2.0 mg/dl or 1.5 times that of the pre-implant creatinine level, severe acidemia, and volume overload. RESULTS: Of 107 consecutive patients who underwent HeartMate II implantation at our center and had been supported for > 30 days, 15 (13 men and 2 women) required post-implant RRT. Of the 15 patients, 3 received CVVHD and 12 received CVVHD and hemodialysis. Renal function improved within 2 months of support compared with average values before support (creatinine clearance, 64 ± 39 vs 92 ± 55 ml/min, p = 0.041; glomerular filtration rate, 46.9 ± 20.7 vs 73.2 ± 38.9 ml/min/1.73 m(2); p = 0.032). Renal function improved after HeartMate II implantation in 10 patients, and RRT was removed. Of these 10 patients, 2 underwent heart transplantation 4 months after RRT was removed, 1 underwent heart and kidney transplantation 4 years later, 2 died at home of conditions unrelated to renal function 6 months after RRT was removed, and 5 are awaiting heart transplantation, with good quality of life. CONCLUSIONS: In this study, patients who experienced clinical recovery after the LVAD implant had subsequent recovery of renal function after continuous-flow LVAD support.
BACKGROUND: Renal function is often compromised in patients with advanced heart failure. METHODS: We evaluated renal function in heart failurepatients supported by the HeartMate II (Thoratec Corporation, Pleasanton, CA) continuous-flow left ventricular assist device (LVAD) who required renal replacement therapy (RRT) by continuous venovenous hemofiltration dialysis (CVVHD) or hemodialysis, or both. Indications for RRT included oliguria (urine < 400 ml/day) unresponsive to diuretic therapy for > 24 hours with a creatinine level > 2.0 mg/dl or 1.5 times that of the pre-implant creatinine level, severe acidemia, and volume overload. RESULTS: Of 107 consecutive patients who underwent HeartMate II implantation at our center and had been supported for > 30 days, 15 (13 men and 2 women) required post-implant RRT. Of the 15 patients, 3 received CVVHD and 12 received CVVHD and hemodialysis. Renal function improved within 2 months of support compared with average values before support (creatinine clearance, 64 ± 39 vs 92 ± 55 ml/min, p = 0.041; glomerular filtration rate, 46.9 ± 20.7 vs 73.2 ± 38.9 ml/min/1.73 m(2); p = 0.032). Renal function improved after HeartMate II implantation in 10 patients, and RRT was removed. Of these 10 patients, 2 underwent heart transplantation 4 months after RRT was removed, 1 underwent heart and kidney transplantation 4 years later, 2 died at home of conditions unrelated to renal function 6 months after RRT was removed, and 5 are awaiting heart transplantation, with good quality of life. CONCLUSIONS: In this study, patients who experienced clinical recovery after the LVAD implant had subsequent recovery of renal function after continuous-flow LVAD support.
Authors: Samuel T Coffin; Dia R Waguespack; Nicholas A Haglund; Simon Maltais; Jamie P Dwyer; Mary E Keebler Journal: Cardiorenal Med Date: 2015-01-09 Impact factor: 2.041
Authors: Colleen K McIlvennan; Kate H Magid; Amrut V Ambardekar; Jocelyn S Thompson; Daniel D Matlock; Larry A Allen Journal: Circ Heart Fail Date: 2014-10-07 Impact factor: 8.790
Authors: Meredith A Brisco; Stephen E Kimmel; Steven G Coca; Mary E Putt; Mariell Jessup; Wilson W H Tang; Chirag R Parikh; Jeffrey M Testani Journal: Circ Heart Fail Date: 2013-11-08 Impact factor: 8.790
Authors: Abhijit Naik; Shahab A Akhter; Savitri Fedson; Valluvan Jeevanandam; Jonathan D Rich; Jay L Koyner Journal: Am J Nephrol Date: 2014-02-15 Impact factor: 3.754
Authors: Daniel W Ross; Gerin R Stevens; Rimda Wanchoo; David T Majure; Sandeep Jauhar; Harold A Fernandez; Massini Merzkani; Kenar D Jhaveri Journal: Clin J Am Soc Nephrol Date: 2017-10-25 Impact factor: 8.237
Authors: Jennifer Sherwin; Elizabeth Thompson; Kevin D Hill; Kevin Watt; Andrew J Lodge; Daniel Gonzalez; Christoph P Hornik Journal: Cardiol Young Date: 2018-07-11 Impact factor: 1.093